Taken together, targeting the TGF-β pathway may be a promising alternative treatment against pancreatic cancer-induced hyperglycemia by preventing β-cell apoptosis and reducing hepatic gluconeogenesis. The gene discussed is TGFB1; the disease is familial pancreatic carcinoma.